Jeffrey Weber, MD, PhD
Nivolumab (Opdivo) demonstrated a sustained efficacy benefit versus ipilimumab (Yervoy) as an adjuvant therapy in patients with high-risk resected stage III/IV melanoma.
in Melanoma, discussed the promise of nivolumab in this setting and a general overview of the melanoma treatment landscape.
OncLive: Please provide some background of the CheckMate-238 trial.
: At the 2018 ASCO Annual Meeting, I reported on the updated results from this large phase III double-blind trial. It had an active control arm. Patients with a high risk of recurrence—50% or higher risk of recurrence beyond 5 years—who also had stage IIIb, IIIc, or IV melanoma, were randomly allocated to either nivolumab, the PD-1 antibody, or ipilimumab, the CTLA-4 antibody.
... to read the full story